Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine with anticonvulsant properties. It is a Schedule IV controlled substance.
## Primary Indications
* Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years and older.
* Off-label uses may include other seizure types and anxiety disorders.
## Adult Dosing
* **Lennox-Gastaut Syndrome:** Initial dose is typically 5 mg twice daily. Dose may be increased by 5-10 mg every week to a maximum of 20 mg twice daily (40 mg/day).
* **Titration:** Clobazam should be initiated at a low dose and gradually increased to minimize withdrawal symptoms.
## Pediatric Dosing
* **Lennox-Gastaut Syndrome (2 to <10 years or <30 kg):** Initial dose is typically 2.5 mg twice daily. Dose may be increased by 2.5-5 mg every week to a maximum of 10 mg twice daily (20 mg/day).
* **Lennox-Gastaut Syndrome (≥10 years or ≥30 kg):** Initial dose is typically 5 mg twice daily. Dose may be increased by 5-10 mg every week to a maximum of 10 mg twice daily (20 mg/day).
## Dose Adjustments
* **Hepatic Impairment:** No specific dose adjustments are recommended, but caution is advised due to potential for accumulation.
* **Renal Impairment:** No specific dose adjustments are recommended, but caution is advised.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
## Adverse Effects
Common: Somnolence, drooling, constipation, decreased appetite, fatigue, respiratory infections, pyrexia.
Serious: Severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), suicidal ideation, dependence, withdrawal symptoms, paradoxical reactions.
## Key Drug Interactions
* **CNS Depressants:** Increased risk of sedation and respiratory depression (e.g., alcohol, opioids, other benzodiazepines, sedating antihistamines, antipsychotics).
* **CYP2C19 Substrates:** Clobazam is a moderate inhibitor of CYP2C19. Concomitant use with CYP2C19 substrates may increase their plasma concentrations (e.g., omeprazole, diazepam, phenytoin).
* **Strong CYP3A4 Inhibitors:** May increase clobazam levels.
* **Strong CYP3A4 Inducers:** May decrease clobazam levels.
* **Antiepileptic Drugs (AEDs):** Potential for altered efficacy of concomitant AEDs. Monitor therapeutic drug levels if clinically indicated.
## Monitoring
* Monitor for effectiveness in seizure control.
* Monitor for signs of sedation, behavioral changes, and suicidal ideation.
* Monitor for signs of withdrawal upon discontinuation.
* Monitor for severe skin reactions.
## Clinical Pearls
* Clobazam has a long half-life, which may allow for less frequent dosing and smoother titration.
* Abrupt discontinuation can lead to withdrawal symptoms, including seizures. Tapering is recommended.
* Due to the risk of severe skin reactions, patients should be advised to seek immediate medical attention if they develop a rash, blistering, or peeling of the skin.
* Clobazam is approved for LGS, but its use for other epilepsy syndromes or anxiety is considered off-label.
---
*This information is for educational purposes and does not substitute for professional medical advice. Always consult the current prescribing information and a qualified healthcare provider for any medication-related questions or decisions.*
